Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Other financing activities (2016 - 2023)

Historic Other financing activities for Spyre Therapeutics (SYRE) over the last 7 years, with Q2 2023 value amounting to $1.8 million.

  • Spyre Therapeutics' Other financing activities fell 1199.8% to $1.8 million in Q2 2023 from the same period last year, while for Jun 2023 it was $6.5 million, marking a year-over-year decrease of 2214.21%. This contributed to the annual value of $7.1 million for FY2022, which is 1153.27% down from last year.
  • According to the latest figures from Q2 2023, Spyre Therapeutics' Other financing activities is $1.8 million, which was down 1199.8% from $1.7 million recorded in Q1 2023.
  • Spyre Therapeutics' Other financing activities' 5-year high stood at $2.1 million during Q3 2021, with a 5-year trough of $1.1 million in Q1 2019.
  • Its 5-year average for Other financing activities is $1.7 million, with a median of $1.7 million in 2020.
  • Per our database at Business Quant, Spyre Therapeutics' Other financing activities skyrocketed by 3614.86% in 2020 and then plummeted by 3185.29% in 2022.
  • Quarter analysis of 5 years shows Spyre Therapeutics' Other financing activities stood at $1.2 million in 2019, then soared by 36.15% to $1.6 million in 2020, then increased by 29.9% to $2.1 million in 2021, then tumbled by 31.85% to $1.4 million in 2022, then grew by 24.39% to $1.8 million in 2023.
  • Its last three reported values are $1.8 million in Q2 2023, $1.7 million for Q1 2023, and $1.4 million during Q4 2022.